Scienture subsidiary issued new patent covering SCN-102

Scienture (SCNX) LLC, a wholly owned subsidiary of Scienture Holdings, announced that the U.S. Patent and Trademark Office, USPTO, has issued a new patent, No. 12,156,869, further strengthening the intellectual property position and coverage for the Company’s SCN-102 product. The ‘869 patent is in addition to the previously granted patent for SCN-102 by the USPTO, No. 11,890,273. The ‘869 patent and the ‘273 patent, both titled, “LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE,” cover stable, liquid pharmaceutical compositions of Losartan and methods of treating patients in need of Losartan by administration of the novel formulations described.